NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome

@article{Deacon2015NNZ2566AN,
  title={NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome},
  author={Robert M. J. Deacon and Larry Glass and Michael F. Snape and Michael J. Hurley and F. J. Altimiras and Rodolfo R. Biekofsky and Patricia Cogram},
  journal={NeuroMolecular Medicine},
  year={2015},
  volume={17},
  pages={71-82}
}
AbstractFragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in the pathogenesis of the disease, and many agents that target the underlying pathophysiology of FXS have focused on mGluR5 modulation. In the present work, a novel pharmacological approach for FXS is investigated. NNZ-2566, a synthetic analog of a naturally occurring neurotrophic peptide derived from insulin-like growth factor-1 (IGF-1), was administered to… 
Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy
TLDR
The present findings support the viability of S1R as a therapeutic target inFXS, and the clinical potential of blarcamesine in FXS and other neurodevelopmental disorders.
Effects of the Sigma-1 Receptor Agonist Blarcamesine in a Murine Model of Fragile X Syndrome: Neurobehavioral Phenotypes and Receptor Occupancy
TLDR
The present findings support the viability of S1R as a therapeutic target in Fragile X syndrome, and the clinical potential of blarcamesine in FXS and other neurodevelopmental disorders.
Neuroinflammation links COVID-19 and fragile X syndrome: Role of MMP-9, IGF-1, IL-10, metformin, statins and curcumin
TLDR
Deep study of these processes that involve both FXS and COVID-19, would facilitate the discovery of potential therapeutic targets and drug development for these diseases.
IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3
TLDR
The findings of this study show the therapeutic potential effect of IGF-1 injection for SCA3 to prevent the exacerbation of disease progress and decreased immunofluorescence staining in aggresome formation and ataxin-3 mutant protein levels, possibly through the enhancement of autophagy.
The novel potent GSK3 inhibitor AF3581 reverts fragile X syndrome phenotype.
TLDR
AF3581, a potent GSK3 inhibitor that was recently discovered, is used in an in vivo FXS mouse model to elucidate the crucial role of GSK 3 in specific behavioral patterns (locomotor activity, sensorimotor gating and social behavior) associated with this disease.
Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders
TLDR
The role of IGF-1 in the molecular etiologies of Rett Syndrome and Autism Spectrum Disorders is reviewed in addition to the accumulating evidence from early clinical studies highlighting the possibility of IGF -1 and related compounds as potential treatments for these childhood-onset neurodevelopmental disorders.
Pharmacotherapy for Fragile X Syndrome: Progress to Date
TLDR
A brief summary of the prevalence, phenotypic characteristics, genetic causes and molecular functions of FMRP in the brain, discusses the most recent finding in FXS drug development, and summarizes FXS trials utilizing symptomatic treatment is offered.
Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety
TLDR
Data indicate that acamprosate, and not calcium, improves function reminiscent of reduced anxiety-like behavior and hyperactivity in Fmr1 KO mice and that acamrosate attenuates select electrophysiological and molecular dysregulation that may play a role in the pathophysiology of FXS.
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
TLDR
The pathways that were recently linked to the physiopathology of FXS (mGluR, GABAR, insulin, Insulin-like Growth Factor 1 (IGF-1), MPP-9, serotonin, oxytocin and endocannabinoid signaling) and that suggest new approaches to find an effective therapy for this disorder are discussed.
Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome
TLDR
It is shown that the potentiation of extrasynaptic GABA receptors alone, by gaboxadol, is sufficient to normalize numerous behavioral deficits in the FXS model using endpoints that are directly translatable to the clinical presentation of FXS.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen
TLDR
Evidence is provided that activation of a particular neuronal receptor can improve symptoms in both mice and humans and suggests that STX209 may be a potentially effective therapy to treat the core symptoms of fragile X syndrome.
NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke
IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions
TLDR
The research suggests that small neuropeptides have advantages over growth factors in the treatment of brain injury, and that modified neuropePTides designed to overcome the limitations of their endogenous counterparts represent a novel strategy of pharmaceutical discovery for neurological disorders.
Dysregulation of mTOR Signaling in Fragile X Syndrome
TLDR
Elevated mTOR signaling may provide a functional link between overactivation of group I mGluRs and aberrant synaptic plasticity in the fragile X mouse, mechanisms relevant to impaired cognition in fragile X syndrome.
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
TLDR
Systemic treatment of MeCP2 mutant mice with an active peptide fragment of Insulin-like Growth Factor 1 (IGF-1) extends the life span of the mice, improves locomotor function, ameliorates breathing patterns, and reduces irregularity in heart rate.
A fragile balance: FMR1 expression levels.
TLDR
The presence of elevated FMR1 mRNA in all patients suggests that these syndromes may represent a gain-of-function effect from the elevated message levels.
Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
TLDR
Previous findings using lymphocytes for studies of neuropsychiatric disorders are verified and evidence that misregulation of mTOR signaling observed in the FXS mouse model also occurs in human FXS is provided and may provide useful biomarkers for designing targeted treatments in FXS.
...
1
2
3
4
5
...